1,587
Views
1
CrossRef citations to date
0
Altmetric
Public Health – Article Commentary

The approach of World Health Organization to articulate the role and assure impact of vaccines against antimicrobial resistance

, , , & ORCID Icon
Article: 2145069 | Received 28 Sep 2022, Accepted 18 Oct 2022, Published online: 24 Nov 2022

References

  • World Health Organization (WHO). Global antimicrobial resistance surveillance system (GLASS) report: early implementation 2020 [Internet]. 2020. https://www.who.int/glass/resources/publications/early-implementation-report-2020/en/.
  • Wi T, Lahra MM, Ndowa F, Bala M, Dillon JAR, Ramon-Pardo P, Eremin SR, Bolan G, Unemo M. Antimicrobial resistance in Neisseria gonorrhoeae: global surveillance and a call for international collaborative action. Plos Med. 2017;14(7):1. doi:10.1371/journal.pmed.1002344.
  • Murray CJ, Ikuta KS, Sharara F, Swetschinski L, Robles Aguilar G, Gray A, Han C, Bisignano C, Rao P, Wool E, et al. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022;399(10325):629–5. doi:10.1016/S0140-6736(21)02724-0.
  • World Bank. Drug-resistant infections: a threat to our economic future. Washington (DC): World Bank; 2017.
  • de Kraker MEA, Stewardson AJ, Harbarth S. Will 10 million people die a year due to antimicrobial resistance by 2050? Plos Med. 2016;13(11):e1002184. doi:10.1371/journal.pmed.1002184.
  • World Health Organization. Global action plan on antimicrobial resistance. WHO Press; 2015. p. 1–28.
  • Bloom DE, Black S, Salisbury D, Rappuoli R. Antimicrobial resistance and the role of vaccines. Proc Natl Acad Sci USA. 2018;115(51):12868–71. doi:10.1073/pnas.1717157115.
  • Wellcome Trust. Vaccines to tackle drug resistant infections an evaluation of R&D opportunities [Internet]. 2018. https://vaccinesforamr.org/wp-content/uploads/2018/09/Vaccines_for_AMR.pdf.
  • Bell BG, Schellevis F, Stobberingh E, Goossens H, Pringle M. A systematic review and meta-analysis of the effects of antibiotic consumption on antibiotic resistance. BMC Infect Dis. 2014;14(13):1–25. doi:10.1186/1471-2334-14-13.
  • Lewnard JA, Lo NC, Arinaminpathy N, Frost I, Laxminarayan R. Childhood vaccines and antibiotic use in low- and middle-income countries. Nature. 2020;581(7806):94–99. doi:10.1038/s41586-020-2238-4.
  • Klugman KP, Madhi SA, Huebner RE, Kohberger R, Mbelle N, Pierce N. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N Engl J Med. 2003;349(14):1341–48. doi:10.1056/NEJMoa035060.
  • Klugman KP, Black S. Impact of existing vaccines in reducing antibiotic resistance: primary and secondary effects. Proc Natl Acad Sci USA. 2018;115(51):12896–901. doi:10.1073/pnas.1721095115.
  • Buckley BS, Henschke N, Bergman H, Skidmore B, Klemm EJ, Villanueva G, Garritty C, Paul M. Impact of vaccination on antibiotic usage: a systematic review and meta-analysis. Clin Microbiol Infect. 2019;25(10):1213–25. doi:10.1016/j.cmi.2019.06.030.
  • Bilcke J, Antillón M, Pieters Z, Kuylen E, Abboud L, Neuzil KM, Pollard AJ, Paltiel AD, Pitzer VE. Cost-effectiveness of routine and campaign use of typhoid Vi-conjugate vaccine in Gavi-eligible countries: a modelling study. Lancet Infect Dis. 2019;19(7):728–39. doi:10.1016/S1473-3099(18)30804-1.
  • Federal Disease Surveillance and Response Unit Pakistan. Weekly field epidemiology report. 2020;2(2).
  • World Health Organization (WHO). Immunization agenda 2030: a global strategy to leave no one behind. 2020.
  • World Health Organization (WHO). Leveraging vaccines to reduce antibiotic use and prevent antimicrobial resistance [Internet]. 2021. https://www.who.int/publications/m/item/leveraging-vaccines-to-reduce-antibiotic-use-and-prevent-antimicrobial-resistance.
  • Vekemans J, Hasso-Agopsowicz M, Kang G, Hausdorff WP, Fiore A, Tayler E, Klemm EJ, Laxminarayan R, Srikantiah P, Friede M, et al. Leveraging vaccines to reduce antibiotic use and prevent antimicrobial resistance: a World Health Organization action framework. Clin Infect Dis [Internet]. 2021 Jan 25. doi:10.1093/cid/ciab062.
  • Malarski M, Hasso-Agopsowicz M, Soble A, Mok W, Mathewson S, Vekemans J. Vaccine impact on antimicrobial resistance to inform Gavi, the vaccine alliance’s 2018 vaccine investment strategy: report from an expert survey [version 1; peer review: 2 approved]. F1000research. 2019;8. doi:10.12688/f1000research.20100.1.
  • Tacconelli E, Carrara E, Savoldi A, Harbarth S, Mendelson M, Monnet DL, Pulcini C, Kahlmeter G, Kluytmans J, Carmeli Y, et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis. 2018 Mar;18(3):318–27. doi:10.1016/S1473-3099(17)30753-3.
  • World Health Organization (WHO). 2021. Bacterial vaccines in clinical and preclinical development: an overview and analysis. 2022.
  • World Health Organization. Antibacterial Agents in preclinical development. 2019.
  • World Health Organization. Antibacterial Agents in Clinical Development. 2017.
  • 2019 antibacterial agents in clinical development. 2019.
  • Kim C, Holm M, Frost I, Hasso-Agopsowicz M, Abbas K. Global and regional burden of attributable and associated bacterial antimicrobial resistance avertable by vaccination: modelling study. SSSRN; 2022.
  • AMR Tripartite. Monitoring and evaluation of the global action plan on antimicrobial resistance: framework and recommended indicators [Internet]. Geneva PP - Geneva: World Health Organization; 2019. https://apps.who.int/iris/handle/10665/325006.
  • IFPMA. Supporting appropriate recognition and action for vaccination in AMR national action plans [Internet]. 2021. https://www.ifpma.org/wp-content/uploads/2021/11/CRA_LS_IFPMA_publication.pdf.